CoChat

Lofexidine for Opiate Detoxification: Review of Recent Randomised and Open Controlled Trials

Open access
Strang, John, Bearn, Jenny, Gossop, Michael · 1999 · The American Journal on Addictions
Cited by 77

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The objective of this article was to review the data from recently published trials of lofexidine in the treatment of opiate withdrawal, with particular attention to evidence on efficacy, side‐effects (particularly hypotension), and the acceptability of this new treatment to the patient population. The authors reviewed data contained within peer‐reviewed published reports of clinical trials of lofexidine compared with detoxification using reducing doses of the opiate agonist methadone or the alpha‐adrenergic agonist clonidine. Five published reports of clinical trials of lofexidine have been identified from peer‐reviewed journals in the eight years between 1990 and 1998‐all published within the last three years. Three of the reports compare lofexidine with clonidine, while the remaining two compare it with methadone detoxification. The three comparisons with clonidine find lofexidine to be similar in its moderating effect on the withdrawal syndrome, but without the same extent of problems with hypotension. Comparisons with methadone show a more rapid resolution of withdrawal symptoms with lofexidine—particularly with the accelerated 5‐day lofexidine protocol. Such problems of hypotension as were encountered with lofexidine were adequately managed with dose reduction. Acceptability of the treatment to the patient (as measured by retention in treatment) appears to be greater with lofexidine than clonidine, although possibly less than with methadone. Lofexidine is an alpha‐2 adrenergic agonist that is increasingly used in the management of opiate withdrawal—notably in the UK. The available data indicate that it is a useful new addition to the armamentarium of the clinician. Future studies should explore its application with improved protocols and in new treatment settings. This article reviews the recent advances in the study of lofexidine as a new treatment for opiate detoxification. It examines the background of the development and introduction of lofexidine into the U.K., with data on the extent to which it is now used in the U.K. in the treatment of opiate addiction.1 A review is then provided of the published evidence on the use of lofexidine in the management of opiate detoxification, mainly concentrating on the data from recent double‐blind randomised trials. Finally, the possible future role of lofexidine in this field is considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/105504999305749

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 77

Metadata

Authors
Strang, J., Bearn, J., & Gossop, M.
Venue
The American Journal on Addictions
Publisher
Wiley
Published
1999-10
Volume
8
Issue
4
Pages
337-348
ISSN
  • 1055-0496 (ISSN-L)
  • 1521-0391
OpenAlex
W2171397714
Cited by
77
References
1
FWCI
2.61
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lofexidine for Opiate Detoxification: Review of Recent Randomised and Open Controlled Trials. https://app.cochat.ai/papers/10.1080/105504999305749
The paper
Strang, J., Bearn, J., & Gossop, M. (1999). Lofexidine for Opiate Detoxification: Review of Recent Randomised and Open Controlled Trials. The American Journal on Addictions. https://doi.org/10.1080/105504999305749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.